HC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 468.18% from the company’s previous close.

Several other equities research analysts also recently commented on the stock. Wedbush reiterated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Wells Fargo & Company cut their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Finally, UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Trading Down 5.9 %

Zentalis Pharmaceuticals stock opened at $1.76 on Thursday. The company has a market capitalization of $125.43 million, a PE ratio of -0.71 and a beta of 1.75. The stock has a 50-day moving average price of $2.06 and a two-hundred day moving average price of $2.87. Zentalis Pharmaceuticals has a 12 month low of $1.61 and a 12 month high of $16.27.

Insider Activity at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was bought at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the purchase, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. The trade was a 120.27 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jan Skvarka bought 60,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the purchase, the director now owns 149,551 shares of the company’s stock, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Almitas Capital LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 69.3% in the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock worth $4,929,000 after purchasing an additional 665,968 shares in the last quarter. Primecap Management Co. CA lifted its stake in shares of Zentalis Pharmaceuticals by 1.5% in the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company’s stock valued at $4,608,000 after buying an additional 22,600 shares in the last quarter. Verition Fund Management LLC grew its holdings in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after buying an additional 951,500 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Zentalis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company’s stock worth $3,979,000 after acquiring an additional 20,864 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Zentalis Pharmaceuticals by 9.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company’s stock worth $3,756,000 after acquiring an additional 110,882 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.